Expertise in
9
conditions

Binghe H. Xu

Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
Expertise in
9
conditions
Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 

Overview

Binghe Xu practices practicing medicine in Beijing, China.

Xu is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Agranulocytosis, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Mastectomy.

They are actively involved in clinical research, co-authoring 369 peer reviewed articles and participating in 6 clinical trials.

Locations

Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100006, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drug: Afuresertib
Study Phase: Phase 3
A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Pamiparib
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Enrollment Status: Unknown
Publish Date: April 19, 2017
Intervention Type: Drug
Study Drugs: 5-Fu/Epirubicin/CTX Following Docetaxel, Docetaxel/Capecitabine Followed by Capecitabine/Epirubicin/Cyclophosphamide
Study Phase: Phase 3
View 5 Less Clinical Trials

369 Total Publications

A predictive model of survival in early-stage medullary breast carcinoma: a population-based study.
A predictive model of survival in early-stage medullary breast carcinoma: a population-based study.
Journal: Hong Kong medical journal = Xianggang yi xue za zhi
Published: August 12, 2026

Frequently Asked Questions about Binghe H. Xu

Is Binghe H. Xu a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Binghe H. Xu is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Binghe H. Xu participate in research or clinical trials?

Yes. Binghe H. Xu has published 369 articles and abstracts on conditions like Breast Cancer. You can view a list of Binghe H. Xu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xu's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile